NCT06892743 Analgesic Efficacy of Ultrasound-guided External Oblique Intercostal Plane Block Versus Posterior Transversus Abdominis Plane Block in Patients Undergoing Open Nephrectomy
| NCT ID | NCT06892743 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Cairo University |
| Condition | Postoperative Pain |
| Study Type | INTERVENTIONAL |
| Enrollment | 56 participants |
| Start Date | 2025-04-01 |
| Primary Completion | 2026-07 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 56 participants in total. It began in 2025-04-01 with a primary completion date of 2026-07.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Renal cell carcinoma (RCC) accounts for 2-3% of all cancers and is a common malignancy of the genitourinary tract. Open nephrectomy, performed through midline, subcostal, or flank incisions, remains a standard treatment but often results in significant postoperative pain, leading to respiratory muscle dysfunction, increased pulmonary complications, and prolonged hospital stays. Acute surgical pain arises from inflammatory responses, activation of spinal pain pathways, and muscle spasms. While postoperative pain typically improves during recovery, some patients develop chronic postsurgical pain (CPSP), lasting at least two months postoperatively. Opioids and epidural analgesia are commonly used for pain control, but their side effects and invasiveness necessitate safer, effective alternatives. Ultrasound (US)-guided peripheral nerve and field blocks have become integral to multimodal analgesia. One such technique, the \*\*external oblique intercostal plane block (EOIPB)\*\*, was introduced as a modification of fascial plane blocks, targeting anterior and lateral cutaneous nerves (T6-T10). EOIPB offers advantages over quadratus lumborum block (QLB) and erector spinae plane block (ESPB) by being performed in the supine position and providing superior midline analgesia compared to serratus intercostal plane block (SIPB). Similarly, the transversus abdominis plane (TAP) block, particularly the posterior approach, delivers analgesia from T7 to T12 by anesthetizing anterior and lateral cutaneous nerve branches. While case series suggest EOIPB may be effective for post-nephrectomy pain, comparative studies between EOIPB and posterior TAP block in open nephrectomy: Aim of the Study: To evaluate the postoperative analgesic effects of posterior transversus abdominis plane (TAP) block and external oblique intercostal plane block (EOIPB) in patients undergoing open nephrectomy under general anesthesia.
Eligibility Criteria
Inclusion Criteria: * Patients whom diagnosed as having renal carcinoma and scheduled for open nephrectomy under general anesthesia. * ASA class II- III. * Age ≥ 18 and ≤ 70 years. * Body mass index (BMI) less than 40kg/m2. Exclusion Criteria: 1. Patient refusal. 2. Hepatic and renal insufficiency. 3. Unstable cardiovascular or pulmonary disease. 4. History of psychiatric and cognitive disorders. 5. Patients with known sensitivity or contraindications to the drug used. 6. Patients on regular opioid consumption.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06892743 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 70 Years, studying Postoperative Pain. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06892743 currently recruiting?
Yes, NCT06892743 is actively recruiting participants. Contact the research team at abeer_ahmed@kasralainy.edu.eg for enrollment information.
Where is the NCT06892743 trial being conducted?
This trial is being conducted at Maadi, Egypt, Cairo, Egypt.
Who is sponsoring the NCT06892743 clinical trial?
NCT06892743 is sponsored by Cairo University. The trial plans to enroll 56 participants.